AstraZeneca has unveiled a newly expanded manufacturing facility in Texas to the tune of $445m, as the drugmaker aims to meet ...

Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.

With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe’s most dynamic biotech ...

Tubulis has completed a Series C, securing €308m ($361m) to be directed towards advancing clinical development of its ADC ...

A consortium led by Nordic Capital and Permira has raised its bid, though certain shareholder stances remain firm.

Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for 200m yuan ($28m).

The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen ...

Goldman Sachs has secured the top spot as the leading financial adviser in mergers and acquisitions (M&A) based on deal value ...

Kirkland & Ellis has secured the foremost position as a legal adviser in the mergers and acquisitions (M&A) sector in terms ...

Pfizer's Tukysa could become the first update to the maintenance regimen for HER2-positive breast cancer in over a decade if ...

Nabla Bio has entered a new multi-year research collaboration with Takeda to advance AI-driven design of protein therapeutics ...

J&J’s surprise orthopaedic separation announcement arrived hot on the heels of positive Q3 financial results for the company.